Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 15/20 | 0.72 |
| ▸ | CCR4 | P51679 | 1/20 | 0.57 |
| ▸ | NSD2 | O96028 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.50 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25489867 | 0.92 | EHMT2 (0.63) | EHMT2CCR4NSD2KDM4ELMNA | |
| SCHEMBL25489923 | 0.89 | EHMT2 (0.59) | EHMT2CCR4NSD2KDM4ELMNA | |
| SCHEMBL24843852 | 0.88 | EHMT2 (0.69) | EHMT2NSD2LMNA | |
| SCHEMBL25489922 | 0.88 | EHMT2 (0.58) | EHMT2CCR4NSD2KDM4ELMNA | |
| SCHEMBL24844279 | 0.87 | EHMT2 (0.78) | EHMT2NSD2EHMT1 | |
| SCHEMBL30064068 | 0.87 | EHMT2 (0.78) | EHMT2NSD2EHMT1 | |
| SCHEMBL30063292 | 0.86 | EHMT2 (0.66) | EHMT2 | |
| SCHEMBL30064757 | 0.86 | EHMT2 (0.67) | EHMT2EHMT1 | |
| SCHEMBL24844148 | 0.86 | EHMT2 (0.67) | EHMT2EHMT1 | |
| SCHEMBL24844080 | 0.86 | EHMT2 (0.66) | EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | EHMT2 2/4885CCR4 3986/4885NSD2 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.